Q07817 (B2CL1_HUMAN) Homo sapiens (Human)

Bcl-2-like protein 1 UniProtKBInterProSTRINGInteractive Modelling

233 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3); 11 identical sequences

Available Structures

111 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
STRUCTURE OF BCL-XL/BAK PEPTIDE COMPLEX, NMR, MINIMIZED AVERAGE STRUCTURE Heteromer
Q16611;
1-210
Assess
COMPLEX OF BCL-XL WITH PEPTIDE FROM BAD Heteromer
Q92934;
1-209
Assess
Solution structure of BCL-XL bound to P73-TAD peptide Heteromer
O15350;
1-209
Assess
SOLUTION STRUCTURE OF AN APOPTOSIS ACTIVATING PHOTOSWITCHABLE BAK PEPTIDE BOUND to BCL-XL Heteromer
Q16611;
1-209
33B;
Assess
Solution structure of BCL-xL in complex with PUMA BH3 peptide Heteromer
Q9BXH1;
1-209
Assess
TCTP contains a BH3-like domain, which instead of inhibiting, activates Bcl-xL Heteromer
P13693;
1-208
BCT;NA;
Assess
Bcl-xL with mouse Bak BH3 Q75L complex Heteromer
O08734;
1-208
EDO;
Assess
Crystal structure of alpha-beta-foldamer 2c in complex with Bcl-xL Heteromer
O43521;
1-206
CL;SO4;
Assess
Bcl-xL with Bak BH3 complex Heteromer
Q16611;
2-207
GOL;
Assess
Crystal structure of BCL-XL in complex with inhibitor (WEHI-539) Heteromer
1-203
X0B;EDO;SO4;
Assess
Puma BH3 foldamer in complex with Bcl-xL Heteromer
1-202
Assess
Crystal structure of BCL-xL in complex with computationally designed inhibitor protein Heteromer
1-201
Assess
Crystal structure of human bcl-xL bound to trichoplax adhaerens trBak BH3 Heteromer
A0A369S334;
1-200
SO4;
Assess
Crystal structure of Bcl-xL in complex with HBx-BH3 motif Heteromer
I3XMW8;
1-200
Assess
Selective Affimers Recognize BCL-2 Family Proteins Through Non-Canonical Structural Motifs Heteromer
1-199
SO4;
Assess
Bcl-xL complex with Beclin 1 BH3 domain T108D Heteromer
Q14457;
1-198
CL;
Assess
Solution Structure of the Complex Between BCL-xL and the p53 Core Domain determined with PRE restra… Heteromer
P04637;
1-198
ZN;
Assess
Crystal structure of BCL-xL in complex with computationally designed inhibitor protein Heteromer
1-197
Assess
PROTAC6 mediated complex of VHL:EloB:EloC and Bcl-xL Heteromer
P40337; Q15369; Q15370;
1-197
QL8; 17×EDO;GOL; 12×IOD;
Assess
Bcl-xL in complex with Bim-h3Pc-RT Heteromer
O43521;
1-197
EDO;
Assess
BimL12F in complex with Bcl-xL Heteromer
O43521;
1-197
ZN;
Assess
Bcl-xL complex with Beclin 1 BH3 domain T108pThr Heteromer
Q14457;
1-197
Assess
Crystal structure of alpha-beta foldamer 4c in complex with Bcl-xL Heteromer
O43521;
1-197
Assess
Structure of the Bcl-XL:Beclin 1 complex Heteromer
Q14457;
2-198
Assess
Structure of Bcl-xL bound to BimSAHB Heteromer
O43521;
1-196
14×GOL;
Assess
Structure of Bcl-xL bound to BimLOCK Heteromer
O43521;
1-196
GOL;
Assess
Complex of Bcl-xL with its BH3 domain Heteromer
2-197
CA;EPE;EDO;
Assess
Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival protei… Heteromer
Q96LC9;
1-196
Assess
Crystallographic structure of BCL-xL domain-swapped dimer in complex with PUMA BH3 peptide at 2.9A … Heteromer
Q9BXH1;
1-196
Assess
Solution structure of the Bcl-xL/Beclin-1 complex Heteromer
Q14457;
1-196
Assess
Crystal structure of Bcl-xL in complex with BIM BH3 domain Heteromer
O43521;
2-196
Assess
Bcl-xL bound to alpha beta Puma BH3 peptide 5 Heteromer
Q9BXH1;
1-195
15×CD;EDO;
Assess
Crystal structure of Bcl-xL in complex with BID BH3 domain Heteromer
P55957;
4-198
IMD;
Assess
Bim BH3 peptide in complex with Bcl-xL Heteromer
O43521;
1-194
Assess
Crystal structure of human SOUL BH3 domain in complex with Bcl-xL Heteromer
Q9Y5Z4;
4-197
SO4;
Assess
Crystal structure of Bcl-xl bound to BIM-MM Heteromer
O43521;
3-196
Assess
Crystal structure of Bcl-xL in complex with the BaxBH3 domain Heteromer
Q07812;
3-196
Assess
Structure of human Bcl-2 in complex with PUMA BH3 peptide Heteromer
P10415; Q9BXH1;
14-178
Assess
Affimer:BclxL Heteromer
83-197
Assess
Bcl-2 complex with Beclin 1 T108D BH3 domain Heteromer
P10415; Q14457;
29-44
Assess
Bcl-2 alpha beta-1 LINEAR complex Heteromer
O43521; P10415;
29-44
Assess
Bcl-2 alpha beta-1 complex Heteromer
O43521; P10415;
29-44
Assess
Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival protei… Heteromer
P10415; Q96LC9;
29-44
Assess
Crystal structure of Bcl-xL hexamerhomo-6-mer3-196
GOL;
Assess
Crystal structure of Bcl-xL in complex with benzoylurea compound (42)homo-4-mer1-198
X0R; 12×SO4; 20×EDO;
Assess
Crystal structure of BCL-XL bound to compound 7: (R)-3-(Benzylthio)-2-(3-(4-chloro-[1,1':2',1'':3''…homo-2-mer1-201
QHV;EDO;
Assess
Bcl-XL 3D Domain Swapped Dimerhomo-2-mer1-200
Assess
Crystal structure of Bcl-xL in complex with benzoylurea compound (39b)homo-2-mer1-198
X0D;SO4; 12×EDO;
Assess
alpha/beta foldamer in complex with Bcl-xLhomo-2-mer1-198
11×EDO;
Assess
Crystal structure of BCL-XL bound to compound 8: (R)-3-(Benzylthio)-2-(3-(2-((4'-chloro-[1,1'-biphe…homo-2-mer1-197
XOY;SO4;EDO;
Assess
CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH COMPOUND 1620116, CRYSTAL FORM 2homo-2-mer1-197
V9S;
Assess
Crystal structure of BCL-XL bound to compound 13: (R)-2-(3-([1,1'-Biphenyl]-4-carbonyl)-3-(4-methyl…homo-2-mer1-197
QHP;SO4;EDO;
Assess
Crystal structure of BCL-XL bound to compound 2: (2R)-3-(Benzylsulfanyl)-2-({[(4-methylphenyl)methy…homo-2-mer1-197
XOU;SO4; 11×EDO;
Assess
Crystal structure of BCL-XL in complex with COMPOUND 1620116, CRYSTAL FORM 1homo-2-mer1-196
V9S;
Assess
Crystal structure analysis of cp3 bound BCLxlhomo-2-mer1-196
GOL;JJ9;
Assess
Bcl-xL in complex with inhibitor (Compound 10)homo-2-mer1-196
38H;EDO;ACT;
Assess
Crystal structure of BCL-XL in complex with W1191542homo-2-mer1-196
X0J; 11×EDO;CL;
Assess
Crystal structure of BCL-XL bound to compound 15: (R)-2-(3-(2-((4'-Chloro-[1,1'-biphenyl]-2-yl)meth…homo-2-mer1-196
EDO;SO4;QHJ;
Assess
Crystal structure of BCL-XL bound to compound 12: (R)-2-(3-([1,1'-Biphenyl]-4-carbonyl)-3-(4-methyl…homo-2-mer1-196
SO4;EDO;QHS;
Assess
Discovery of a Potent and Selective BCL-XL Inhibitor That Demonstrates Thrombocytopenia and Inhibit…homo-2-mer2-196
3CQ;
Assess
BCL-XL in a complex with a covalent small molecule inhibitorhomo-2-mer2-196
KBH;BR;
Assess
Crystal structure of Bcl-xL in complex with compound 10homo-2-mer3-196
LC6;PO4;
Assess
NMR STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH, MINIMIZED AVERAGE STRUCTUREmonomer1-210
Assess
Solution structure of BCL-xL containing the alpha1-alpha2 disordered loop determined with selective…monomer1-209
Assess
Solution structure of BCL-xL determined with selective isotope labelling of I,L,V sidechainsmonomer1-209
Assess
Solution structure of a Bcl-xL S62E mutantmonomer1-209
Assess
NMR STRUCTURE of Bcl-XLmonomer1-209
Assess
Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based l…monomer1-209
43B;
Assess
Solution structure of the anti-apoptotic protein Bcl-xL complexed with an acyl-sulfonamide-based li…monomer1-209
43B;
Assess
Solution Structure of BCL-xL in its p53-bound conformation determined with selective isotope labell…monomer1-209
Assess
Solution Structure of the Anti-apoptotic Protein Bcl-xL in Complex with "SAR by NMR" Ligandsmonomer1-209
4FC;TN1;
Assess
Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based l…monomer1-209
N3B;
Assess
Crystal structure of BCL-XL in complex with a benzothiazole-based inhibitormonomer3-207
XZM;
Assess
Crystal Structure of Bcl-xL bound to BM903monomer1-199
03B;ZN;ACT;
Assess
Crystal structure of p53/BCL-xL fusion complexmonomer3-201
ZN;
Assess
The Crystal Structure of p53/BCL-xL fusion complex from Biortus.monomer3-201
ZN;
Assess
Crystal Structure of Bcl-xL bound to BM501monomer1-197
B50;GOL;
Assess
Structure of human Bcl-2 in complex with ABT-263monomer14-210
1XJ;
Assess
Human Bcl-XL containing a Phe to Leu mutation at position 146monomer1-197
Assess
Crystal structure of BCL-XL in complex with inhibitor (Compound 3)monomer1-197
H0Y;SO4;EDO;
Assess
The Crystal Structure of human Bcl-2-like protein 1 from Biortusmonomer1-197
SO4;
Assess
Structure of Human Bcl-XL at 1.95 Angstromsmonomer1-196
Assess
Human Bcl-XL containing an Ala to Leu mutation at position 142monomer1-196
Assess
X-RAY STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATHmonomer1-196
Assess
Crystal structure of Bcl-xL in complex with inhibitor (Compound 2).monomer2-197
H1I;
Assess
Crystal structure of BCL-XL in complex with inhibitor (Compound 6)monomer2-197
X8U;
Assess
Human Bcl-XL containing a Phe to Trp mutation at position 97monomer1-196
Assess
Crystal structure of Bcl-xL in complex with tetrahydroisoquinoline-pyridine based inhibitorsmonomer2-196
RQ7;
Assess
Crystal structure of cp1 bound BCLxlmonomer2-196
JFF;
Assess
Crystal structure of Bcl-Xl complex with 4-(5-butyl-3-(hydroxymethyl)-1-phenyl-1h-pyrazol-4-yl)-3-(…monomer2-196
0Q5;IMD;
Assess
Human Bcl-XL containing a Glu to Leu mutation at position 92monomer2-196
Assess
Human Bcl-xL containing a Trp to Ala mutation at position 137monomer2-196
Assess
Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based l…monomer2-196
LI0;
Assess
Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based l…monomer2-196
LIW;
Assess
Structure of human Bcl-2 in complex with fragment/ABT-263 hybridmonomer14-207
J1T;
Assess
Crystal structure of Bcl-xL in complex with a Quinazoline sulfonamide inhibitormonomer4-197
HI0;CL;GOL;
Assess
Crystal structure of Bcl-xL in complex with ABT-737monomer4-197
CL;N3C;GOL;
Assess
Structure of human Bcl-2 in complex with THIQ-phenyl pyrazole compoundmonomer14-204
J1Q;ACT;
Assess
Structure of human Bcl-2 in complex with analogue of ABT-737monomer14-178
J1H;
Assess
anti-apoptotic protein BCL-2-M12monomer14-178
IQ8;
Assess
Crystal structure of Bcl-2 in complex with the novel orally active inhibitor S55746monomer28-95
F3Q;
Assess
Structure of the transmembrane helix of BclxL in phospholipid nanodiscsmonomer202-233
Assess
Structure of the C-terminal domain of BCL-XL in membranemonomer206-233
Assess
crystal structure of BCL-2 with venetoclaxmonomer29-44
LBM;2PE;
Assess
crystal structure of BCL-2 F104L mutation with venetoclaxmonomer29-44
LBM;PEG;
Assess
crystal structure of BCL-2 G101A mutation with venetoclaxmonomer29-44
LBM;PEG;
Assess
crystal structure of BCL-2 G101V mutation with S55746monomer29-44
F3Q;
Assess
Crystal Structure of human Bcl-2 in complex with a small molecule inhibitor targeting Bcl-2 BH3 dom…monomer29-44
1E9;
Assess
crystal structure of BCL-2 G101V mutation with venetoclaxmonomer29-44
LBM;PEG;CL;
Assess
Bcl-2-xL complexed with compound 35monomer29-44
ULL;
Assess
HUMAN BCL-2 WITH PHENYLACYLSULFONAMIDE INHIBITORmonomer89-91
398;
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
4qnq.5.Amonomer0.691-197
1XJ;97.85
Assess
2b48.1.Amonomer0.511-200
100.00
Assess

2 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 34qnq.5.Amonomer0.671-197
84.75
Assess
Isoform 31lxl.1.Amonomer0.551-209
90.91
Assess